Drug intelligence / Profile preview

IM21

Development stage: Phase 1
Lead developer: Immunochina Pharmaceuticals
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Parenteral

Overview

IM21 is an autologous CAR-T cell therapy developed by Imunopharm Technology for the treatment of relapsed and refractory multiple myeloma. It consists of T cells engineered to express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA) on myeloma cells, enabling specific recognition and lysis of BCMA-expressing tumor cells. Administered via parenteral infusion following leukapheresis and manufacturing, it is currently in Phase 1 clinical trials, including studies for elderly patients and those with measurable disease after at least three prior lines of therapy.[1][2][3]

Other names: IM21 CAR-T cellsIM-21 CAR-T cellsIM 21 CAR-T cells

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on IM21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM21.

Explore the full profile